References
- Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Philipps J, Turner RT. The effect of risedronate on bone mineralization as measured by microcomputed tomography with synchroton radiation. Correlation to histomorphometric indices of turnover. Bone 2005;37:1–9.
- Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008;42:456–466.
- Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005;16:475–482.
- Reginster JY, Neuprez A, Bruyère O. Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol 2008;4:941–951.
- Ringe JD, Body JJ. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol 2007;25:766–774
- Mueller A, Dittrich R, Binder H, Kuehnel W, Maltaris T, Hoffmann I, Beckmann MW. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005;153:107–113.
- Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Investig 2000;106:1553–1560.
- Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841–1850.